Aug 21, 2025 • GlobeNewswire
SOMEWHAT-BULLISH
Telix 2025 Half-Year Results: Strong commercial performance enables investment for long-term growth
MELBOURNE, Australia and INDIANAPOLIS, Aug. 21, 2025 ( GLOBE NEWSWIRE ) -- Telix Pharmaceuticals Limited ( ASX: TLX, NASDAQ: TLX, "Telix" ) today announces its financial results for the half-year ended 30 June 2025. All figures are in USD unless stated otherwise.
Aug 12, 2025 • Benzinga
NEUTRAL
Telix Pharmaceuticals Limited ( TLX ) Shares Fall Amid SEC Subpoena - Hagens Berman - Telix Pharmaceuticals ( NASDAQ:TLX )
SAN FRANCISCO, Aug. 12, 2025 ( GLOBE NEWSWIRE ) -- On July 23, 2025, investors in Telix Pharmaceuticals Limited ( NASDAQ:TLX ) saw the price of their American Depositary Shares significantly fall after the company revealed that it received a subpoena from the SEC.
Aug 05, 2025 • Benzinga
NEUTRAL
Telix Pharmaceuticals Limited ( TLX ) Shares Fall Amid SEC Subpoena -- Hagens Berman - Telix Pharmaceuticals ( NASDAQ:TLX )
SAN FRANCISCO, Aug. 05, 2025 ( GLOBE NEWSWIRE ) -- On July 23, 2025, investors in Telix Pharmaceuticals Limited ( NASDAQ:TLX ) saw the price of their American Depositary Shares significantly fall after the company revealed that it received a subpoena from the SEC.
Jul 29, 2025 • Benzinga
NEUTRAL
Telix H1 2025 Results: Investor Webcast Notification - Telix Pharmaceuticals ( NASDAQ:TLX )
MELBOURNE, Australia and INDIANAPOLIS, July 30, 2025 ( GLOBE NEWSWIRE ) -- Telix Pharmaceuticals Limited TLXTLX "Telix" ) today advises that it will release its financial results for the half-year ended 30 June 2025 on Thursday 21 August 2025.
Jul 29, 2025 • GlobeNewswire
NEUTRAL
Telix H1 2025 Results: Investor Webcast Notification
MELBOURNE, Australia and INDIANAPOLIS, July 30, 2025 ( GLOBE NEWSWIRE ) -- Telix Pharmaceuticals Limited ( ASX: TLX, NASDAQ: TLX, "Telix" ) today advises that it will release its financial results for the half-year ended 30 June 2025 on Thursday 21 August 2025.
Jul 28, 2025 • Benzinga
NEUTRAL
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited - TLX - Telix Pharmaceuticals ( NASDAQ:TLX )
NEW YORK, July 28, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Telix Pharmaceuticals Limited ( "Telix" or the "Company" ) TLX. Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.